Results 211 to 220 of about 2,074,577 (363)

Hepatocellular Carcinoma [PDF]

Mayo Clinic Proceedings, 2017
openaire   +2 more sources

Polysaccharide Adjuvants as Innate Immune Trainers: Bridging Pattern Recognition Receptor (PRR) Activation and Metabolic Reprogramming for Synthetic Vaccine Design

Advanced Science, EarlyView.
Polysaccharides modulate immune responses by engaging pattern recognition receptors (PRRs) to induce T‐cell activation. In vaccine design, their particle size critically influences lymph node targeting and activation mechanisms. By engineering structural complexity and multivalent PRR engagement, polysaccharides enable precise modulation of immune ...
Jeong Hyun Moon, May Thazin Phoo, Yubin Kim, Jinsung Ahn, April Kim, Jutaek Nam, Soo‐Hong Lee, James J. Moon, Sejin Son   +8 more
wiley   +1 more source

Hyaluronic Acid Hydrogel Implants for Sustained Release of Oxaliplatin and Resiquimod to Prevent Hepatocellular Carcinoma Recurrence Post‐Radiofrequency Ablation

Advanced Science, EarlyView.
Preparation of a biopolymer‐based immune implant (BI) for the sustained release of R848 and oxaliplatin (OXA), enabling immune activation and preventing recurrence after radiofrequency ablation (RFA) treatment in hepatocellular carcinoma (HCC). Abstract Hepatocellular carcinoma (HCC) remains a global challenge due to limited therapies and high ...
Yuezhan Shan, Hongyu Chu, Sheyu Ye, Guofeng Ji, Jiayi Zhao, Xinghui Si, Yumin Zhong, Youmao Tao, Jingwei Shi, Xuedong Fang   +9 more
wiley   +1 more source

Sorafenib in advanced hepatocellular carcinoma.

New England Journal of Medicine, 2008
G. Spinzi, S. Paggi
semanticscholar   +2 more sources

Nutritional c‐Fos Induction Rewires Hepatic Metabolism and Can Promote Obesity‐Associated Hepatocellular Carcinoma

Advanced Science, EarlyView.
It is shown that hepatic c‐Fos responds to feeding, altering de novo lipogenesis, glycolysis, and a wide range of steatosis‐associated metabolic signaling pathways. Obesogenic diets cause hepatic c‐Fos overexpression, insulin resistance, and the induction of metabolic reprogramming‐related genes.
Ao Li, Eduardo H. Gilglioni, Wadsen St‐Pierre‐Wijckmans, Leila Hosseinzadeh, Christelle Veyrat‐Durebex, Sumeet Pal Singh, Roberto Coppari, Latifa Bakiri, Esteban N. Gurzov   +8 more
wiley   +1 more source

Splenectomy and hepatocellular carcinoma: Cause or confounder? [PDF]

World J Hepatol
Kim SH.
europepmc   +1 more source

Detection of fusion transcripts in the serum samples of patients with hepatocellular carcinoma [PDF]

, 2019
Yanping Yu, Allan Tsung, Silvia Liu, Michael Nalesnick, David A. Geller, George K. Michalopoulos, Jianhua Luo   +6 more
openalex   +1 more source

A Novel FGFR3‐Targeting Antibody‐Drug Conjugate Induces Tumor Cell Apoptosis through the cGAS–STING Pathway in Bladder Cancer

Advanced Science, EarlyView.
LZU‐WZLYCS01 is a novel FGFR3‐targeting ADC for bladder cancer with 7‐ethyl‐9‐fluorocamptothecin (A2) as its cytotoxic payload. LZU‐WZLYCS01 intracellularly releases A2, which targets MAD2L1 to activate the cGAS‐STING pathway and induce tumor cell apoptosis.
Shu Cui, Xiongfei Luo, Guangrui Fan, Jingqi Jiang, Yingru Wang, Enguang Yang, Jinpeng Ma, Ze Zhang, Yuhan Wang, Juan Wang, Dengtuo Wang, Hanzhang Wang, Liang Cheng, Junqiang Tian, Zhilong Dong, Yingqian Liu, Zhiping Wang   +16 more
wiley   +1 more source

Ectopic hepatocellular carcinoma of the abdominal wall. [PDF]

Hepatobiliary Surg Nutr
Lai B.
europepmc   +1 more source

Precision treatment in advanced hepatocellular carcinoma.

Cancer Cell
Xupeng Yang, Chen Yang, Shu Zhang, Haigang Geng, Andrew X. Zhu, René Bernards, Wenxin Qin, Jia Fan, Cun Wang, Qiang Gao   +9 more
semanticscholar   +1 more source